“LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT”, Mediterr J Hematol Infect Dis, vol. 16, no. 1, p. e2024039, Apr. 2024, doi: 10.4084/MJHID.2024.039.